Differences in toxicity and outcome associated with circadian variations between patients undergoing daytime and evening radiotherapy for prostate adenocarcinoma

This retrospective study tested the hypothesis that disease control and treatment-related toxicity in patients undergoing high-dose radiotherapy (HDRT) for prostate cancer varies in a circadian manner.

Patients with localized prostate adenocarcinoma receiving HDRT (median 78 Gy) to the prostate and involved seminal vesicle(s) without elective pelvic irradiation were divided into a daytime treatment (before 5 PM) group (n = 267) and evening treatment (after 5 PM) group (n = 142). Biochemical failure (Phoenix definition), acute and late gastrointestinal (GI) and genitourinary toxicities (Common Terminology Criteria for Adverse Events version 4), biochemical failure-free survival (BFFS) and freedom from late toxicity were assessed. Analyses were performed by binary logistic regression and Cox proportional hazard regression. The median follow-up was 68 months, and 75% of patients were ≥70 years old. Evening HDRT was significantly associated with worse freedom from ≥grade 2 late GI complications (hazard ratio = 2. 96; p < 0. 001). The detrimental effect of evening HDRT was significant in patients older than 70 years old (p < 0. 001) but not in younger patients (p = 0. 63). In a subgroup of propensity score-matched cohort with T2b-T3 disease (n = 154), the 5-year BFFS was worse in the evening group than the daytime group (72% vs. 85%, hazard ratio = 1. 95, p = 0. 05). Our study indicates that evening HDRT may lead to more GI complications, especially in older patients, and worse BFFS in patients with T2b-T3 disease.

Chronobiology international. 2016 Jan 28 [Epub ahead of print]

Feng-Ming Hsu, Wei-Hsien Hou, Chao-Yuan Huang, Chia-Chun Wang, Chiao-Ling Tsai, Yu-Chieh Tsai, Hong-Jeng Yu, Yeong-Shiau Pu, Jason Chia-Hsien Cheng

a Division of Radiation Oncology, Department of Oncology , National Taiwan University Hospital , Taipei , Taiwan. , b Department of Radiation Oncology , City of Hope Cancer Center , Duarte , California , USA. , c Department of Urology , National Taiwan University College of Medicine , Taipei , Taiwan. , a Division of Radiation Oncology, Department of Oncology , National Taiwan University Hospital , Taipei , Taiwan. , a Division of Radiation Oncology, Department of Oncology , National Taiwan University Hospital , Taipei , Taiwan. , d Division of Medical Oncology, Department of Oncology , National Taiwan University Hospital , Taipei , Taiwan. , c Department of Urology , National Taiwan University College of Medicine , Taipei , Taiwan. , c Department of Urology , National Taiwan University College of Medicine , Taipei , Taiwan. , a Division of Radiation Oncology, Department of Oncology , National Taiwan University Hospital , Taipei , Taiwan.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe